Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome

Hasle, Henrik; Heegaard, Erik D.; Kerndrup, Gitte; Jensen, Inger Marie; Peterslund, Niels Anker; Hornsleth, A

doi:10.1016/0145-2126(95)00123-9

Cited by 8 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the absence of an efficient humoral and/or cellular immune response, the infection can cause persistent BM suppression manifested by chronic anaemia but not supposedly immune-mediated symptoms such as rash and arthralgia [132]. Predisposing conditions include congenital immunodeficiencies, leukaemia, lymphoma, myelodysplastic syndrome, BM and solid organ transplantation, chemotherapy, and infection with human immunodeficiency virus [50,51,[132][133][134][135][136][137][138][139][140][141][142].…”

Section: B19 Infection In Immunocompromised Individualsmentioning

confidence: 99%

Clinical aspects of parvovirus B19 infection

Broliden

Tolfvenstam

Norbeck

2006

Journal of Internal Medicine

190

203

View full text Add to dashboard Cite

Parvovirus B19 is a significant human pathogen that causes a wide spectrum of clinical complications ranging from mild, self-limiting erythema infectiosum in immunocompetent children to lethal cytopenias in immunocompromised patients and intrauterine foetal death in primary infected pregnant women. The infection may also be persistent and can mimic or trigger autoimmune inflammatory disorders. Another important clinical aspect to consider is the risk of infection through B19-contaminated blood products. Recent advances in diagnosis and pathogenesis, new insights in the cellular immune response and newly discovered genotypes of human parvoviruses form a platform for the development of modern therapeutic and prophylactic alternatives.

show abstract

Section: B19 Infection In Immunocompromised Individualsmentioning

confidence: 99%

Clinical aspects of parvovirus B19 infection

Broliden

Tolfvenstam

Norbeck

2006

Journal of Internal Medicine

190

203

View full text Add to dashboard Cite

show abstract

“…AILD‐type, even in the absence of lymphoma involvement. Erythroblastic hyperplasia can be observed during infection with Parvovirus B19 58,59 . Giant erythroblasts and multinucleated erythroblasts are dispersed in the bone marrow.…”

Section: Haematopoietic Cell Line Modificationsmentioning

confidence: 99%

“… 13 This infection occurs frequently in immunosuppressed patients, particularly after bone marrow or organ transplantation, or in patients with myelodysplasia. 58 A haemophagocytic syndrome can be associated. 59 The diagnosis is confirmed by three techniques: serum assay for specific anti‐HPV 19 antibodies (IgM, IgD), demonstration in the blood of the presence of HPV‐19 DNA by PCR technique, demonstration by in‐situ hybridization in tissue sections of HPV‐19 DNA or RNA in giant proerythroblasts or in normal erythroblasts.…”

Section: Haematopoietic Cell Line Modificationsmentioning

confidence: 99%

Bone marrow manifestations of infections and systemic diseases observed in bone marrow trephine biopsy

et al. 2000

View full text Add to dashboard Cite

Bone marrow modifications resulting from infections and systemic diseases can be studied by analysis of morphology and aetiology. Two types of lesions or modifications can be observed, those occurring in the connective tissue comprising inflammatory processes, acute and chronic, as well as immune reactions, and those involving the normal haematopoietic cell lines, with possible hyperplastic or aplastic changes in one or more cell lines. The main lesions are described (oedema, haemorrhage, necrosis, suppuration, granulomas, lymphoid nodules and hyperplasia, immunoblastic or plasmacytic hyperplasia), as well as the main aetiologies. In association, the three main haematopoietic cell lines show hyperplasia, hypoplasia, aplasia of one or all of the cell lines, sometimes with dysmyelopoiesis. The stroma and vessel reactions comprise myelofibrosis, gelatinous transformation or amyloid deposits. The methods for identifying aetiological agents are emphasized. It should also be stressed that malignant neoplasias of different types involving the bone marrow can be responsible for such inflammatory or immune reactions.

show abstract

“…Parvovirus B19 [148][149][150][151][152] and HHV-6 infection, 153 both in children and in adults, have been reported as mimicking MDS blood and marrow features, and these syndromes spontaneously disappeared in 1-2 months.…”

Section: Viral Infectionsmentioning

confidence: 99%

Infections in myelodysplastic syndromes

et al. 2012

View full text Add to dashboard Cite

Myelodysplastic syndromes are associated with a risk of severe infections. While neutropenia is likely to be the main predisposing factor, several other immune defects have been reported, including impaired neutrophil function, B-, T-and NK-cell defects and the possible consequences of iron overload due to red blood cell transfusions. The advanced age of most patients, their frequent comorbidities, and the fact that drugs such as hypomethylating agents and lenalidomide, which are effective in myelodysplastic syndromes but can transiently worsen neutropenia, may increase the risk of infection and their severity in this context. The majority of infections in myelodysplastic syndromes are bacterial, while the incidence of fungal infections is not well known and viral infections seem to be rare. No prophylactic measures against infections have demonstrated efficacy in myelodysplastic syndromes. However, pending more data, we propose here some recommendations for the management of patients with myelodysplastic syndromes. In the future, an important contribution can be made by prospective trials testing the efficacy of prophylactic and therapeutic approaches to infection in these patients, especially in the context of the new drugs available for myelodysplastic syndromes. ABSTRACTand respective bacterial, fungal, and viral causes of infection in MDS. Most of these data are retrospective. Some are compromised by inconsistencies in the definition of the infectious events or, although taken from therapeutic trials, may be biased by patient eligibility criteria. In a recent US retrospective series of 273 untreated low-or intermediate-1 risk MDS patients who died in the period from 1980 to 2004, infection was the primary cause of death, accounting for 38% of the total, followed by AML transformation (15%) and hemorrhage (13%).9 Pneumonia was the most common infection, responsible for 40% of infectious deaths. Infection, mostly of a bacterial origin, was microbiologically documented in 30% of the cases of pneumonia in these MDS patients. As this study covered three decades, it was possible to show a significant decrease in the incidence of infectious deaths over time, likely attributable to improved supportive care. Another US survey of the Medicare population (an insurance covering more than 97% of all US citizens aged 65 years or over) indicated that, in a population of 1.3 million people over the age of 65 years followed between the years 2003 and 2005, patients with MDS had a higher prevalence of infections than the non-MDS Medicare population (22.5% vs. 6.

show abstract

Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome

Cited by 8 publications

References 16 publications

Clinical aspects of parvovirus B19 infection

Clinical aspects of parvovirus B19 infection

Bone marrow manifestations of infections and systemic diseases observed in bone marrow trephine biopsy

Infections in myelodysplastic syndromes

Contact Info

Product

Resources

About